Amneal Pharmaceuticals' IPX-203, a combination of carbidopa and levodopa, successfully met primary and secondary endpoints in a Phase III trial for Parkinson's disease patients experiencing motor fluctuations. This oral gastric-retentive capsule offers a potential improvement over current treatments like Rytary.